Envigo, a leading provider of nonclinical contract research services and research models, has invested in an expansion of its global bioanalytical capabilities in response to increased market demand from its biopharmaceutical customers.
The investments to increase global capacity have been made to support customers’ discovery, preclinical and clinical drug development efforts for small and large molecules.
Envigo has significantly increased bioanalytical capacity over the last three years as part of a growth strategy dedicated to the investment in people, streamlined processes, technology platforms, and efficient laboratory space.
Recent investments include SCIEX™ API 6500+™ mass spectrometers, SCIEX™ API 4500™ mass spectrometers and on-line solid phase extraction automation.
These strategic investments increase Envigo’s ability to support the growing need for highly-sensitive methods and fit-for-purpose development programs, supported by a highly experienced team with a focus on efficient method development, transfer and validation across three continents.
We are committed to and continue to build out our global bioanalytical capabilities. We are dedicated to developing and delivering effective solutions to support the increasing demands of our customers by shortening lead times, increasing efficiency and throughput while maintaining the highest quality in communication, data interpretation and delivery.
Building on our 2018 bioanalytical investments, in 2019 we are scheduled to increase mass spectrometer capability, expand our laboratory footprint, and increase efficiencies by dedicating further space for wet labs, automation and analytical instrumentation.”
Lee Coney, Chief Scientific Officer at Envigo